BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 58.77 CNY | +1.01% |
|
+7.85% | -12.19% |
| Apr. 02 | Tranche Update on Bloomage BioTechnology Corporation Limited's Equity Buyback Plan announced on August 17, 2023. | CI |
| Feb. 29 | Bloomage Biotech Names CFO | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 35.32 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.27 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -12.19% | 3.87B | C | ||
| -2.86% | 87.31B | A- | ||
| +3.95% | 40.86B | A- | ||
| -23.26% | 29.36B | B- | ||
| +58.30% | 24.49B | A | ||
| -15.33% | 17.31B | C | ||
| -19.73% | 11.62B | B- | ||
| -15.61% | 11.31B | D+ | ||
| -44.23% | 11.26B | B | ||
| +5.24% | 8.31B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 688363 Stock
- Ratings Bloomage BioTechnology Corporation Limited
